178 related articles for article (PubMed ID: 24085600)
21. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
Kang Q; Vahl CI
Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
[TBL] [Abstract][Full Text] [Related]
22. Statistical aspects of bioequivalence testing between two medicinal products.
Zintzaras E
Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
[TBL] [Abstract][Full Text] [Related]
23. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.
Wijnand HP
Comput Methods Programs Biomed; 2003 Jan; 70(1):21-35. PubMed ID: 12468124
[TBL] [Abstract][Full Text] [Related]
24. The existence of sequence effect in cross-over bioequivalence trials.
Zintzaras E
Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):241-4. PubMed ID: 11420897
[TBL] [Abstract][Full Text] [Related]
25. Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers.
Almeida S; Filipe A; Almeida A; Gich I; Antonijoan R; Puntes M; Barbanoj M; Cruz Caturla M
Arzneimittelforschung; 2006; 56(2):70-5. PubMed ID: 16572920
[TBL] [Abstract][Full Text] [Related]
26. Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel-group study of lamotrigine.
Yang J; Ma P; Bullman J; Nicholls A; Chen C
Br J Clin Pharmacol; 2019 Mar; 85(3):563-569. PubMed ID: 30511473
[TBL] [Abstract][Full Text] [Related]
27. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
Knahl SIE; Lang B; Fleischer F; Kieser M
Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
[TBL] [Abstract][Full Text] [Related]
28. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.
Karalis V; Macheras P; Bialer M
CNS Drugs; 2014 Jan; 28(1):69-77. PubMed ID: 24092569
[TBL] [Abstract][Full Text] [Related]
29. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
30. Optimal adaptive sequential designs for crossover bioequivalence studies.
Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
[TBL] [Abstract][Full Text] [Related]
31. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
32. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of zonisamide orally dispersible tablet and immediate-release capsule formulations: results from two open-label, randomized-sequence, single-dose, two-period, two-treatment crossover studies in healthy male volunteers.
Maanen Rv; Bentley D
Clin Ther; 2009 Jun; 31(6):1244-55. PubMed ID: 19695391
[TBL] [Abstract][Full Text] [Related]
34. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
35. Individual bioequivalence revisited.
Chen ML; Lesko LJ
Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
[TBL] [Abstract][Full Text] [Related]
36. Sequential bioequivalence approaches for parallel designs.
Fuglsang A
AAPS J; 2014 May; 16(3):373-8. PubMed ID: 24526610
[TBL] [Abstract][Full Text] [Related]
37. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
38. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
Yu YP; Yan XY; Yao C; Xia JL
Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
[TBL] [Abstract][Full Text] [Related]
39. Cost-efficient higher-order crossover designs in comparative bioavailability studies.
Zhou J; Yuan Y; Reynolds R; Raber S; Li Y
Clin Pharmacokinet; 2006; 45(6):623-32. PubMed ID: 16719543
[TBL] [Abstract][Full Text] [Related]
40. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; RodrÃguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
